

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:

WOLOZIN et al.

Serial Number: 09/901,187

Group Art Unit: not assigned

Filed: July 9, 2001

Examiner: not assigned

For:

Methods for Preventing Neural Tissue Damage and for the Treatment of Alpha-

Synuclein Diseases

Response to Notice to File Missing Parts

Commissioner for Patents Washington, D.C. 20231

October 25, 2001

Sir:

In response to the Notice to File Missing Parts of Application, dated October 3, 2001, enclosed herewith are the executed Declaration and the Powers of Attorney (3), along with the fee of \$65.00. In addition, submitted with these papers is an assignment, and the recordation fee of \$40.00 is included in the amount of the enclosed check.

Respectfully submitted,

Mary E. Gormley

Attorney for Applicants Registration No. 34,409

Docket No.: PAN01/002US Panacea Pharmaceuticals, Inc. 9700 Great Seneca Hwy. Rockville, Maryland 20850

Tel: (240) 453-6295

Enclosures: Copy of Notice; Declaration; Powers of Attorney; Check (\$105.00)

I certify that this correspondence is being deposited with the US Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Date:

10/25/01

By:

Mary E. Gormley

DEC ME STATE OF THE PERSONS ACTOR AC

& sector

PTO/SB/21 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Acres 1985 persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	09/901,187
Filing Date	07/09/2001
First Named Inventor	Wolozin et al.
Group Art Unit	n/a
Examiner Name	n/a
Attorney Docket Number	PAN01/002US

Total Number of Pages in This	Submission 2+ Attorney Docket Numb	er PAN01/002US				
		k all that apply)				
Fee Transmittal Form Fee Attached Amendment / Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53	Assignment Papers (for an Application) Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Address Terminal Disclaimer Request for Refund CD, Number of CD(s) Remarks	After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please identify below): Formal Drawings (6 sheets)				
SIGI	NATURE OF APPLICANT, ATTORNEY, OR	AGENT				
Firm or Mary E. C	Gormley					
Signature						
Date 6/25	01					
CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: Typed or printed name Mary E. Gormley						
Typed or printed name Mary E. Gormley						

PTO/SB/17 (10-01)
Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
o a collection of information unless it displays a valid OMB control number. aperwork Reduction Act of 1995, no persons are required to re-

TRANSMITTAL for FY 2002

Patent fees are subject to annual revision.

105.00 TOTAL AMOUNT OF PAYMENT (\$)

Name (Print/Type)

Signature

Mary E. Gormley

spend to a delication of intermitation and a series of the				
Complete if Known				
Application Number	09/901,187			
Filing Date	07/09/2001			
First Named Inventor	Wolozin et al.			
Examiner Name	n/a			
Group Art Unit	n/a			
Attorney Docket No.	PAN01/002US			

	METHOD OF PAYMENT	FEE CALCULATION (continued)		
	The Commissioner is hereby authorized to charge	3. ADDITIONAL FEES		
	indicated fees and credit any overpayments to: Deposit	Large Small		
	Account Number		ee Paid	
	Deposit	Code (\$) Code (\$)	65.00	
	Account Name	105 130 205 65 Surcharge - late filing fee or oath	05.00	
	Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17	127 50 227 25 Surcharge - late provisional filing fee or cover sheet		
	Applicant claims small entity status.	139 130 139 130 Non-English specification		
	See 37 CFR 1.27	147 2,520 147 2,520 For filing a request for ex parte reexamination		
	2.	112 920* 112 920* Requesting publication of SIR prior to Examiner action		
4	FEE CALCULATION	113 1,840* 113 1,840* Requesting publication of SIR after Examiner action		
	1. BASIC FILING FEE	115 110 215 55 Extension for reply within first month		
:=d:	Large Entity Small Entity	116 400 216 200 Extension for reply within second month		
	Fee Fee Fee Fee Description Code (\$) Code (\$) Fee Paid	117 920 217 460 Extension for reply within third month		
:=5	101 740 201 370 Utility filing fee	118 1,440 218 720 Extension for reply within fourth month		
Ţ.	106 330 206 165 Design filling fee	128 1,960 228 980 Extension for reply within fifth month		
Hais	107 510 207 255 Plant filing fee	119 320 219 160 Notice of Appeal		
38	108 740 208 370 Reissue filing fee	120 320 220 160 Filing a brief in support of an appeal		
• =	114 160 214 80 Provisional filing fee	121 280 221 140 Request for oral hearing		
ľŲ	SUBTOTAL (1) (\$)	138 1,510 138 1,510 Petition to institute a public use proceeding	 [
4		140 110 240 55 Petition to revive - unavoidable		
:2	2. EXTRA CLAIM FEES Fee from	141 1,280 241 640 Petition to revive - unintentional		
	Extra Claims below Fee Paid	142 1,280 242 640 Utility issue fee (or reissue)		
ræ:	Total Claims	143 460 243 230 Design issue fee		
	Claims	525 21. 515		
	Multiple Dependent	122 130 122 130 Petitions to the Commissioner		
	Large Entity Small Entity	123 50 123 50 Processing fee under 37 CFR 1.17(q)		
	Fee Fee Fee Fee Description	126 180 126 180 Submission of Information Disclosure Stmt	40.00	
	Code (\$) Code (\$) 103 18 203 9 Claims in excess of 20	581 40 581 40 Recording each patent assignment per 2 property (times number of properties)	40.00	
	102 84 202 42 Independent claims in excess of 3	146 740 246 370 Filing a submission after final rejection (37 CFR § 1.129(a))		
	104 280 204 140 Multiple dependent claim, if not paid	149 740 249 370 For each additional invention to be		
	109 84 209 42 ** Reissue independent claims over original patent	examined (37 CFR § 1.129(b))		
	110 18 210 9 ** Reissue claims in excess of 20 and over original patent	179 740 279 370 Request for Continued Examination (RCE)		
	and over original paterit	169 900 169 900 Request for expedited examination of a design application		
	SUBTOTAL (2) (\$)	Other fee (specify)		
	**or number previously paid, if greater, For Reissues, see above	*Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$) 105	.00	
7	CUDARTED DV	Complete (if applied has		
ſ	SUBMITTED BY	Complete (if applicable)		

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Registration No.

(Attorney/Agent)

34,409

Telephone

240-453-8496



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:

WOLOZIN et al.

Serial Number: 09/901,187

Group Art Unit: not assigned

Filed: July 9, 2001

Examiner: not assigned

For:

Methods for Preventing Neural Tissue Damage and for the Treatment of Alpha-

Synuclein Diseases

Submission of Formal Drawings

Commissioner for Patents Washington, D.C. 20231

October 25, 2001

Sir:

Applicants hereby submit six (6) sheets of formal drawings, Figures 1 - 3, which are in accordance with the drafting rules. It is respectfully requested that these drawings be approved and made of record in this application.

No fee is required with this paper.

Respectfully submitted,

Mary E. Gormley

Attorney for Applicants Registration No. 34,409

Docket No.: PAN01/002US Panacea Pharmaceuticals, Inc. 9700 Great Seneca Hwy. Rockville, Maryland 20850

Tel: (240) 453-6295

Enclosures: Formal Drawings (6 sheets), Figures 1 - 3

I certify that this correspondence is being deposited with the US Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231

Date: 10/25/01

Ву: 7

Mary E. Gormley











COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, D.C. 20231 www.uspto.gov

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

09/901.187

07/09/200

Benjamin Wolozin

PAN01/002

29100 PANACEA PHARMACEUTICALS, INC. 9700 GREAT SENECA HIGHWAY ROCKVILLE, MD 20850



CONFIRMATION NO. 6018 FORMALITIES LETTER *OC000000006834888*

Date Mailed: 10/03/2001

NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

Filing Date Granted

An application number and filing date have been accorded to this application. The item(s) indicated below. however, are missing. Applicant is given TWO MONTHS from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The oath or declaration is unsigned.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(I) of \$65 for a small entity in compliance with 37 CFR 1.27, must be submitted with the missing items identified in this letter.
- The balance due by applicant is \$ 65.


The application is informal since it does not comply with the regulations for the reason(s) indicated below.

The required item(s) identified below must be timely submitted to avoid abandonment:

- Substitute drawings in compliance with 37 CFR 1.84 because:
 - drawing sheets do not have the appropriate margin(s) (see 37 CFR 1.84(q)). Each sheet must include a top margin of at least 2.5 cm. (1 inch), a left side margin of at least 2.5 cm. (1 inch), a right side margin of at least 1.5 cm. (5/8 inch), and a bottom margin of at least 1.0 cm. (3/8 inch);
- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8. 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content







For questions regarding compliance to these requirements, please contact:

■ For Rules Interpretation, call (703) 308-4216

1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE